Janus Henderson Group PLC Acquires 44,575 Shares of InMode Ltd. $INMD

Janus Henderson Group PLC increased its holdings in InMode Ltd. (NASDAQ:INMD) by 5.0% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 932,132 shares of the healthcare company’s stock after purchasing an additional 44,575 shares during the period. Janus Henderson Group PLC owned approximately 1.47% of InMode worth $12,752,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Royal Bank of Canada lifted its stake in InMode by 5.7% in the first quarter. Royal Bank of Canada now owns 242,398 shares of the healthcare company’s stock worth $4,299,000 after purchasing an additional 13,032 shares during the last quarter. AQR Capital Management LLC bought a new position in shares of InMode during the first quarter valued at about $317,000. Goldman Sachs Group Inc. grew its stake in shares of InMode by 234.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,123,756 shares of the healthcare company’s stock valued at $19,935,000 after buying an additional 788,157 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of InMode by 132.9% in the second quarter. American Century Companies Inc. now owns 44,240 shares of the healthcare company’s stock worth $639,000 after buying an additional 25,246 shares during the period. Finally, Marshall Wace LLP increased its holdings in shares of InMode by 270.7% in the second quarter. Marshall Wace LLP now owns 555,573 shares of the healthcare company’s stock worth $8,022,000 after buying an additional 405,707 shares during the period. Institutional investors own 68.04% of the company’s stock.

InMode Price Performance

INMD opened at $15.37 on Wednesday. InMode Ltd. has a one year low of $12.72 and a one year high of $16.74. The business has a 50 day simple moving average of $14.44 and a two-hundred day simple moving average of $14.23. The firm has a market capitalization of $883.47 million, a price-to-earnings ratio of 11.30 and a beta of 1.89.

InMode (NASDAQ:INMD) last issued its quarterly earnings data on Wednesday, May 6th. The healthcare company reported $0.25 earnings per share for the quarter, missing analysts’ consensus estimates of $0.30 by ($0.05). InMode had a return on equity of 13.47% and a net margin of 23.27%.The business had revenue of $82.02 million during the quarter, compared to the consensus estimate of $79.84 million. During the same quarter in the prior year, the business posted $0.31 earnings per share. InMode’s quarterly revenue was up 5.3% compared to the same quarter last year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Barclays set a $19.00 target price on InMode and gave the company an “overweight” rating in a report on Thursday, May 7th. Robert W. Baird lowered their price objective on InMode from $17.00 to $14.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. One analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $16.00.

InMode Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.